Literature DB >> 23111414

Determinants of fatigue in Crohn's disease patients.

Lauran Vogelaar1, Adriaan van't Spijker, Antonie J P van Tilburg, Ernst J Kuipers, Reinier Timman, Christien J van der Woude.   

Abstract

OBJECTIVE: Crohn's disease (CD) is often associated with severe fatigue. Little is known about patients who may be at the highest risk for fatigue. Therefore, we assessed the disease phenotype and factors related to fatigue in the presence of CD in two different populations.
METHODS: Patients presenting at the clinic of a referral hospital and a general hospital were included in the study. They completed questionnaires including the Checklist Individual Strength, the Hospital Anxiety and Depression Scale, a questionnaire on disease activity, and one on medication use. The Montreal classification and sociodemographics were obtained from medical records. Hemoglobin and C-reactive protein levels were measured at baseline.
RESULTS: In total, 425 patients were included (276 women, mean age: 42 years). Compared with patients from the general hospital, patients at the referral hospital had worse disease activity, worse disease behavior, more bowel resections, and a higher percentage of side-effects to medication and use of anti-tumor necrosis factor (TNF). The prevalence of fatigue was significantly higher in the referral patients compared with the general patients (65.7 vs. 52.5%, respectively; P=0.01). Similar results were found in patients in remission (53.3 vs. 40.5%; P=0.061). Factors related to fatigue were the use of anti-TNF at baseline, side-effects to 5-aminosalicylic acid, disease activity, female sex, and shorter disease duration. Furthermore, we found improvement in fatigue and a trend toward lower disease activity after 1 year of anti-TNF use.
CONCLUSION: A high percentage of CD patients suffer from fatigue. As a more aggressive phenotype seems to be associated with more severe fatigue and patients in remission still suffer from fatigue, a multidimensional approach for fatigue is warranted in these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23111414     DOI: 10.1097/MEG.0b013e32835aba83

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

Review 1.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 2.  Preventing disability in inflammatory bowel disease.

Authors:  Patrick B Allen; Corinne Gower-Rousseau; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Therap Adv Gastroenterol       Date:  2017-10-16       Impact factor: 4.409

Review 3.  Unmet Needs in IBD: the Case of Fatigue.

Authors:  Pieter Hindryckx; Debby Laukens; Ferdinando D'Amico; Silvio Danese
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 4.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

5.  Fatigue in out-patients with inflammatory bowel disease: Prevalence and predictive factors.

Authors:  Albert Villoria; Víctor García; Angelina Dosal; Laura Moreno; Antònia Montserrat; Ariadna Figuerola; Diana Horta; Xavier Calvet; María José Ramírez-Lázaro
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

6.  Fatigue in patients with inflammatory bowel disease is associated with distinct differences in immune parameters.

Authors:  Lauran Vogelaar; Colin de Haar; Bas Rj Aerts; Maikel P Peppelenbosch; Reinier Timman; Bettina E Hanssen; C Janneke van der Woude
Journal:  Clin Exp Gastroenterol       Date:  2017-05-02

7.  Cognitive behavioural therapy for the management of inflammatory bowel disease-fatigue with a nested qualitative element: study protocol for a randomised controlled trial.

Authors:  Micol Artom; Wladyslawa Czuber-Dochan; Jackie Sturt; Christine Norton
Journal:  Trials       Date:  2017-05-11       Impact factor: 2.279

Review 8.  Fatigue in Inflammatory Bowel Diseases: Etiologies and Management.

Authors:  Angelica Nocerino; Andrew Nguyen; Manasi Agrawal; Anjali Mone; Komal Lakhani; Arun Swaminath
Journal:  Adv Ther       Date:  2019-11-23       Impact factor: 3.845

9.  High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study.

Authors:  Sara van Gennep; Sanne W Evers; Svend T Rietdijk; Marieke E Gielen; Nanne K H de Boer; Krisztina B Gecse; Cyriel I J Ponsioen; Marjolijn Duijvestein; Geert R D'Haens; Angela G E M de Boer; Mark Löwenberg
Journal:  Inflamm Bowel Dis       Date:  2021-02-16       Impact factor: 5.325

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.